Women’s Health Services Designed Around You

Leaking urine with coughing, sneezing, laughing, or exercise is called stress urinary incontinence. It happens when the pelvic floor muscles and tissues that support the urethra become weakened, allowing urine to escape during moments of increased abdominal pressure. Common causes include pregnancy and childbirth, aging, menopause-related tissue changes, and obesity. Stress incontinence is very common, it affects up to 1 in 3 women, and it is treatable. Pelvic floor muscle exercises (Kegel exercises) are the most effective first-line treatment, with studies showing that about 74% of women report cure or improvement after 3 to 6 months of training. Other options include pessaries, behavioral strategies, and minimally invasive procedures.

A sensation of bulging, heaviness, or "something falling out" of the vagina is the hallmark symptom of pelvic organ prolapse. This occurs when the pelvic floor muscles and connective tissues weaken, allowing the bladder, uterus, or rectum to descend into the vaginal canal. Approximately 40% of women over age 40 are affected. Prolapse is not dangerous, but it can cause discomfort, difficulty with urination or bowel movements, and impact quality of life. Treatment options range from pelvic floor exercises and pessary devices (which provide internal support) to surgical repair, depending on the severity of symptoms and your personal goals.

Several effective non-surgical options are available:

• Pelvic floor muscle training (Kegel exercises): The most effective first-line treatment. A program of at least 8 contractions, 3 times daily, for 3 to 6 months can significantly reduce or eliminate leakage. Working with a pelvic floor physical therapist can improve results.
• Bladder training: A structured program to gradually increase the time between bathroom visits, which is especially helpful for urgency incontinence.
• Pessary: A small, removable device placed in the vagina to support the urethra and reduce stress leakage.
• Medications: For urgency incontinence and overactive bladder, medications can reduce urgency and frequency.
• Lifestyle changes: Weight loss, reducing caffeine and alcohol, managing fluid intake, and treating constipation can all improve symptoms.

Many women see significant improvement with these approaches alone, without ever needing surgery.

Recurrent urinary tract infections (defined as 2 or more UTIs in 6 months, or 3 or more in a year) affect approximately 14% to 25% of women annually. Several factors increase susceptibility:

• Menopause and declining estrogen levels, which change the vaginal and urinary environment
• Sexual activity
• Use of spermicides or diaphragms
• Incomplete bladder emptying
• Pelvic organ prolapse
• Changes in the vaginal microbiome (reduced protective Lactobacillus bacteria)

Prevention strategies include behavioral modifications (adequate hydration, urinating after intercourse), vaginal estrogen therapy for postmenopausal women, and in some cases, low-dose antibiotic prophylaxis. Cranberry products and certain probiotics may also help, though evidence varies. A thorough evaluation can identify your specific risk factors and guide a personalized prevention plan.

A pessary is a small, removable medical device, usually made of medical-grade silicone — that is placed inside the vagina to support the pelvic organs. Pessaries are used to treat pelvic organ prolapse and, in some cases, stress urinary incontinence. They work by physically supporting the bladder, uterus, or rectum in their normal position.

Pessaries come in many shapes and sizes, and your provider will fit one specifically for you. The most commonly used type is a ring pessary. Up to 92% of women can be successfully fitted. Many women learn to insert and remove the pessary themselves, similar to a tampon. For those who prefer not to self-manage, regular follow-up visits (every 3 to 4 months) are recommended for removal, cleaning, and vaginal health checks. Pessaries are a safe, effective, and reversible alternative to surgery.

Persistent bladder pain, especially pain that worsens as the bladder fills and improves after urination, may be a sign of interstitial cystitis/bladder pain syndrome (IC/BPS). This is a chronic condition characterized by bladder pain, pressure, or discomfort along with urinary urgency and frequency, in the absence of infection or other identifiable cause. The exact cause is not fully understood, but it may involve damage to the bladder lining, pelvic floor muscle dysfunction, nerve sensitization, or immune system changes. IC/BPS affects an estimated 3 to 8 million women in the United States. It is a real, recognized medical condition, and effective treatments are available.

When urine tests come back negative for infection but bladder pain persists, several conditions should be considered:

• Interstitial cystitis/bladder pain syndrome (IC/BPS): The most common cause of chronic bladder pain without infection. Symptoms include pain with bladder filling, urinary urgency, and frequency.
• Pelvic floor muscle dysfunction: Tight, overactive pelvic floor muscles can cause pain that feels like it is coming from the bladder.
• Genitourinary syndrome of menopause (GSM): Declining estrogen after menopause can cause urinary burning, urgency, and discomfort that mimics a UTI.
• Endometriosis: Can cause bladder-area pain, especially if it involves the bladder or surrounding tissues.
• Vulvodynia: Chronic vulvar pain that may be perceived as bladder pain.

A thorough evaluation, including a detailed history, pelvic exam with pelvic floor muscle assessment, and sometimes additional testing, can help identify the cause and guide treatment.

Painful intercourse (dyspareunia) after menopause is most commonly caused by genitourinary syndrome of menopause (GSM). As estrogen levels decline, the vaginal tissues become thinner, drier, less elastic, and more fragile. This can cause pain, burning, or irritation during and after intercourse. Approximately 45% to 77% of postmenopausal women experience GSM symptoms, and unlike hot flashes, these symptoms generally worsen over time without treatment.

Effective treatments include vaginal moisturizers and lubricants, low-dose vaginal estrogen (cream, tablet, or ring), vaginal DHEA (prasterone), and ospemifene (an oral medication). Pelvic floor physical therapy can also help, especially if pelvic floor muscle tightness is contributing to pain. These treatments are safe and effective, and most women experience significant improvement.

Interstitial cystitis (IC), also called bladder pain syndrome (BPS), is a chronic condition causing bladder pain, pressure, and discomfort, usually accompanied by urinary urgency and frequency. Unlike a urinary tract infection, IC/BPS is not caused by bacteria, and antibiotics do not help.

Treatment is individualized and typically follows a stepwise approach:

• First-line: Patient education, dietary modifications (avoiding bladder irritants like caffeine, alcohol, acidic foods), stress management, and pelvic floor physical therapy.
• Second-line: Oral medications such as amitriptyline, hydroxyzine, or pentosan polysulfate; bladder instillations.
• Third-line: Procedures such as bladder hydrodistention or Botox injections, for symptoms that do not respond to conservative measures.

An interdisciplinary approach, combining physical therapy, dietary management, stress reduction, and targeted medical therapy, offers the best outcomes.

Chronic pelvic pain is real, and it deserves a thorough evaluation. Many women with chronic pelvic pain have been seen by multiple providers without receiving a clear diagnosis or effective treatment. This does not mean "nothing is wrong." Chronic pelvic pain can arise from multiple overlapping sources, including the bladder, pelvic floor muscles, nerves, reproductive organs, and bowel, and it often requires a comprehensive, multidisciplinary approach.

Common contributing factors include pelvic floor muscle dysfunction, interstitial cystitis/bladder pain syndrome, endometriosis, irritable bowel syndrome, nerve sensitization, and musculoskeletal conditions. A detailed evaluation that includes a thorough history, a careful pelvic and neuromusculoskeletal examination, and screening for overlapping conditions can often identify treatable causes. Effective treatments are available, including pelvic floor physical therapy, medications for nerve-related pain, cognitive behavioral therapy, and targeted procedures.

For most healthy women under age 60, or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks. Hormone therapy remains the most effective treatment for hot flashes, night sweats, and genitourinary symptoms of menopause, reducing the frequency of vasomotor symptoms by approximately 75%.

Like all medications, hormone therapy has both benefits and risks. The benefits include relief of vasomotor symptoms, prevention of bone loss and fractures, and improvement in genitourinary symptoms. The risks include a small increase in the chance of blood clots, stroke, and, with combined estrogen-plus-progestogen therapy, breast cancer. To put this in perspective, the increased risk of these serious events is approximately 1 extra case per 1,000 women per year.

Several factors can influence the safety profile:

• Timing matters: Starting hormone therapy closer to menopause onset (within 10 years) is associated with a more favorable benefit-to-risk ratio than starting later.
• Route of delivery matters: Transdermal (patch) estrogen may carry a lower risk of blood clots and stroke compared with oral estrogen.
• Type of progestogen matters: When a progestogen is needed (for women with a uterus), micronized progesterone may have a more favorable safety profile than synthetic progestins.
• Estrogen-only therapy (for women who have had a hysterectomy) is not associated with an increased risk of breast cancer.

Hormone therapy is not recommended for the prevention of heart disease or dementia. Treatment should be individualized based on your symptoms, health history, and personal risk factors, with periodic reassessment. Your provider will work with you to determine the lowest effective dose for the shortest duration needed to manage your symptoms.

→ Learn more about bone and heart health screening during midlife: Preventive & Lifespan Care

Perimenopause and menopause are related but distinct stages of the reproductive transition:

Perimenopause (the menopausal transition) is the transitional phase before menopause, when hormone levels begin to fluctuate and decline. It typically begins in the mid-40s but can start earlier. During perimenopause, periods become irregular; cycles may be shorter or longer, heavier or lighter, or skipped entirely. Symptoms such as hot flashes, night sweats, sleep disruption, mood changes, and vaginal dryness can begin during this phase. Perimenopause can last several years, on average 4 to 8 years.

Menopause is defined as the point when menstrual periods have stopped for 12 consecutive months, without another medical cause. The average age of natural menopause is 51 years, and it occurs between ages 45 and 56 in 90% of women. After this point, a woman is considered postmenopausal.

Key differences to understand:

• You can still become pregnant during perimenopause, because ovulation may still occur even with irregular periods.
• Symptoms like hot flashes often begin during perimenopause and may peak in the 2 years around the final menstrual period.
• Menopause does not require a blood test to diagnose; it is a clinical diagnosis based on 12 months without a period in a woman over 45.
• Menopause can also occur earlier due to surgery (removal of both ovaries), certain medications, or a condition called primary ovarian insufficiency (menopause before age 40).

Both perimenopause and menopause are natural life stages, not diseases, but the symptoms they cause are real and treatable.

Painful intercourse (dyspareunia) after menopause is most commonly caused by genitourinary syndrome of menopause (GSM). As estrogen levels decline after menopause, the vaginal and vulvar tissues undergo significant changes: they become thinner, drier, less elastic, and more fragile. The vaginal pH rises, and natural lubrication decreases. These changes can cause pain, burning, or irritation during and after intercourse.

GSM affects approximately 45% to 77% of postmenopausal women. Unlike hot flashes, which tend to improve over time, GSM symptoms generally worsen without treatment and do not resolve on their own.

Effective treatments include:

• Vaginal moisturizers and lubricants: The first step, used regularly (moisturizers) or during intercourse (lubricants) to restore comfort.
• Low-dose vaginal estrogen: The preferred hormonal treatment. Available as a cream, tablet, ring, or insert. Improves symptoms by approximately 60% to 80%. Vaginal estrogen acts locally with minimal absorption into the bloodstream and is safe for most women.
• Vaginal DHEA (prasterone): An intravaginal insert that converts to estrogen and testosterone locally. FDA-approved for painful intercourse due to menopause. Improves symptoms by approximately 40% to 80%.
• Oral ospemifene: A non-estrogen oral medication (selective estrogen receptor modulator) that improves vaginal tissue. An option for women who prefer not to use vaginal products. Improves symptoms by approximately 30% to 50%.
• Pelvic floor physical therapy: Especially helpful when pelvic floor muscle tightness or spasm is contributing to pain.

You do not have to accept painful sex as a normal part of aging. These treatments are safe, effective, and can significantly improve comfort and intimacy.

→ Learn more about pelvic floor therapy and conservative treatment options: Non-Surgical Treatment Options

Hot flashes (vasomotor symptoms) are the most common symptom of menopause, affecting 50% to 80% of women. The duration varies significantly from person to person, but research shows they last much longer than many women expect.

Key findings from the landmark SWAN study (Study of Women's Health Across the Nation), which followed over 3,300 women:

• The median total duration of frequent hot flashes was 7.4 years.
• After the final menstrual period, hot flashes persisted for a median of 4.5 years.
• Women who began experiencing hot flashes early, while still having regular or mildly irregular periods, had the longest duration, with a median exceeding 11 years.
• Women whose hot flashes began after menopause had the shortest duration, with a median of 3.4 years.

Duration also varies by race and ethnicity. African American women experience the longest duration (median 10.1 years), while Chinese and Japanese American women tend to have shorter durations (approximately 5 years).

Hot flashes typically peak in frequency and severity in the 2 years surrounding the final menstrual period, then gradually decrease over time, but "gradually" can mean years, not months.

Factors associated with longer-lasting hot flashes include earlier onset of symptoms, higher body weight before menopause, smoking, greater stress, anxiety, and depression.

If hot flashes are interfering with sleep, work, or quality of life, effective treatments are available, both hormonal (estrogen therapy, which reduces frequency by approximately 75%) and non-hormonal (certain antidepressants, gabapentin, and newer targeted therapies). Treatment can be tailored to your symptoms, preferences, and health history.

"Bioidentical" means the hormone has the exact same chemical structure as the hormones your body naturally produces. Bioidentical estradiol and bioidentical (micronized) progesterone are available as FDA-approved prescription medications. These FDA-approved bioidentical hormones have been rigorously tested for safety, effectiveness, consistent dosing, and purity.

Common FDA-approved bioidentical options include:

• Estradiol patches (such as Climara, Vivelle-Dot)
• Estradiol gel or spray
• Estradiol vaginal cream, tablets, rings, or inserts
• Micronized progesterone capsules (Prometrium)
• Combined estradiol/progesterone capsules (Bijuva)

These are the bioidentical hormones recommended by medical societies including the North American Menopause Society (NAMS) and the American College of Obstetricians and Gynecologists (ACOG).

What about compounded bioidentical hormones? Compounded bioidentical hormones are custom-mixed by compounding pharmacies and are NOT FDA-approved. While the term "bioidentical" is often used in marketing to suggest these products are more natural or safer, this is not supported by evidence. The National Academies of Sciences concluded in 2020 that there is insufficient evidence to support the safety or effectiveness of compounded bioidentical hormone therapy. Specific concerns include:

• Inconsistent dosing; the amount of hormone in each dose can vary
• No standardized safety testing or quality control
• No FDA-required warnings or labeling about risks
• Possible contamination or impurities
• Marketing claims of safety (such as "no risk of breast cancer") that are not supported by research

Compounded bioidentical hormones should only be considered if you have a documented allergy to an ingredient in an FDA-approved product. If you are currently using compounded hormones, talk to your provider about switching to an FDA-approved bioidentical option that offers the same hormones with proven quality and safety standards.

Yes. Bladder and urinary symptoms are a recognized part of genitourinary syndrome of menopause (GSM). The bladder, urethra, and pelvic floor tissues all have estrogen receptors, and when estrogen levels decline after menopause, these tissues undergo changes that can cause a range of urinary symptoms.

Common bladder symptoms related to menopause include:

• Urinary urgency: a sudden, strong need to urinate that is difficult to delay
• Urinary frequency: needing to urinate more often than usual, including at night (nocturia)
• Burning or discomfort with urination (dysuria): often mistaken for a urinary tract infection
• Recurrent urinary tract infections (UTIs): declining estrogen changes the vaginal and urethral environment, making infections more likely
• Urinary incontinence: both stress incontinence (leaking with coughing, sneezing, or exercise) and urgency incontinence (leaking associated with a sudden urge) become more common after menopause

These symptoms affect a significant number of postmenopausal women and tend to worsen over time without treatment.

The good news is that vaginal estrogen, applied locally as a cream, tablet, ring, or insert, has been shown to improve urinary urgency, frequency, burning, and reduce the risk of recurrent UTIs. It acts locally on the vaginal and urethral tissues with minimal absorption into the bloodstream. It is important to note that systemic (oral) hormone therapy does not improve urinary symptoms and may actually worsen urinary incontinence, so the type of estrogen and how it is delivered matters.

If you are experiencing bladder symptoms after menopause, a thorough evaluation can determine whether GSM, pelvic floor dysfunction, or another condition is contributing, and guide you toward the right treatment.

→ Learn more about bladder symptoms and treatment options: Bladder & Pelvic Floor Health
→ Explore conservative treatment approaches: Non-Surgical Treatment Options

If you cannot take hormone therapy or simply prefer not to, there are several effective non-hormonal options for managing hot flashes and night sweats. These treatments work through different pathways and can be tailored to your individual needs, symptoms, and health history.

Neurokinin receptor antagonists: A targeted class of therapy
Hot flashes are triggered by changes in the brain's temperature-regulation center (the hypothalamus), where a chemical called neurokinin B becomes overactive after menopause. A newer class of medications blocks this signal directly at its source.

• Fezolinetant (Veozah): Approved by the FDA in 2023. It is taken as a single 45 mg tablet once daily and reduces the frequency of moderate to severe hot flashes by approximately 20–25% more than placebo. Improvement begins as early as the first week. Safety Note: The FDA requires baseline and routine liver monitoring blood tests (at 1, 2, 3, 6, and 9 months) due to rare risks of elevated liver enzymes.
• Elinzanetant (Lynkuet): A dual neurokinin receptor antagonist (NK-1 and NK-3 blocker) FDA-approved in 2025. Taken as 120 mg once daily, it reduces hot flashes by 2.3–3.3 more episodes daily compared to a placebo, while significantly improving sleep disturbances. Clinical trials have not linked it to liver toxicity issues to date. Common side effects are limited to mild headache or fatigue.

Prescription medications used off-label:

• Low-dose paroxetine (7.5 mg nightly): The only SSRI antidepressant explicitly FDA-approved for hot flashes. It improves symptoms by 10–25% over placebo but should not be combined with tamoxifen.
• Venlafaxine & Escitalopram: Commonly utilized off-label; clinical trials demonstrate therapeutic symptom reductions closely rivaling low-dose estrogen routes.
• Gabapentin: Highly useful if hot flashes consistently disrupt nighttime sleeping patterns, as drowsiness is a common secondary effect.
• Oxybutynin: Originally a bladder muscle stabilizer, it shows an impressive 30–50% structural reduction in hot flashes over placebo, though dry mouth and constipation are common.

Clinically proven behavioral therapies:

• Cognitive Behavioral Therapy (CBT): A structured protocol that actively reduces the psychological severity and daily disruption of hot flashes while tracking structural improvements in stress and anxiety.
• Clinical Hypnosis: Formally recommended by medical societies; clinical trials show an average 50–74% reduction in overall hot flash occurrences, alongside notable advancements in deep sleep quality.

What does NOT work: Research has not shown consistent, replicable benefits for hot flashes when using acupuncture, yoga, paced breathing, soy supplements, black cohosh, probiotics, or cannabis products. While fine for general wellness, they are not effective primary options for hot flashes.

• Hormone Safety: Per the 2022 NAMS Position Statement, systemic hormone therapy presents a highly favorable safety scale for healthy symptomatic women under age 60 or within 10 years of menopause onset. Severe complications (VTE, stroke) track minor baseline increases (~1 case per 1,000 women annually).
• Duration Scales: Data extracted from the multi-center SWAN Study confirms a median total duration of frequent hot flashes tracking 7.4 years, with a baseline exceeding 11 years for individuals experiencing early cycle irregularity shifts.
• GSM Success Measures: The American College of Obstetricians and Gynecologists (ACOG) guidelines confirm low-dose localized vaginal estrogen yields a clear 60–80% localized symptom reduction scale for genitourinary symptoms.
• Compounded Therapy (cBHT): A comprehensive 2020 consensus track by the National Academies of Sciences, Engineering, and Medicine found insufficient safety, dosing consistency, or bio-equivalence testing evidence to clinically justify custom compounded hormone paths over tightly controlled FDA-regulated bioidentical lines.

Yes. Many women with pelvic organ prolapse can be effectively managed without surgery. The two main non-surgical options are:

• Pessary: A removable silicone device placed in the vagina to support the prolapsed organs. Up to 92% of women can be successfully fitted. Pessaries can be used long-term and are safe for women of all ages.
• Pelvic floor muscle training (PFMT): Supervised exercises to strengthen the pelvic floor. When combined with a pessary, PFMT has been shown to significantly improve prolapse symptoms compared to either treatment alone.

For women with mild symptoms, a "watch and wait" approach with lifestyle modifications (weight management, avoiding heavy lifting, treating constipation) may also be appropriate. Surgery is reserved for women who do not improve with conservative measures or who prefer a surgical approach.

Yes, Kegel exercises (pelvic floor muscle training) are the most effective first-line treatment for urinary incontinence, supported by high-quality evidence. Key findings from research:

• For stress incontinence: 76% of women reported being cured after pelvic floor muscle training, compared to 9% with no treatment.
• Women who performed exercises were significantly more satisfied with treatment and less likely to need further intervention.
• A program of at least 8 contractions, 3 times daily, held for up to 10 seconds each, is typically recommended.
• Supervised programs (with a pelvic floor physical therapist) produce better results than unsupervised exercise alone.
• Adding biofeedback may improve satisfaction and reduce leakage frequency.

The key to success is consistency. Most women see improvement within 3 to 6 months of regular training. If you have difficulty identifying or contracting your pelvic floor muscles, a pelvic floor physical therapist can help.

A pessary is a medical device made of flexible, medical-grade silicone that is placed inside the vagina to provide support for pelvic organs that have shifted out of position (prolapse) or to help prevent urine leakage (stress incontinence).

How it works: The pessary sits inside the vagina and acts like an internal support structure, holding the bladder, uterus, or rectum in their normal position. It relieves symptoms of heaviness, bulging, and pressure, and can also reduce bladder leakage.

What to expect:

• Your provider will select the right type and size through a fitting process, it may take a few tries to find the best fit.
• The most common type is a ring pessary, which is the first type usually tried.
• Many women learn to insert and remove the pessary themselves for cleaning.
• If you prefer not to self-manage, your provider will schedule regular follow-up visits (typically every 3 to 4 months) for removal, cleaning, and vaginal health checks. Pessaries are a safe, effective, and reversible alternative to surgery.